首页> 美国卫生研究院文献>other >Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
【2h】

Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines

机译:酶促生产的新型线性DNA构建体与用作DNA疫苗的质粒的比较分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The use of DNA to deliver vaccine antigens offers many advantages, including ease of manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial culture, necessitating elements which are either unnecessary for effective gene delivery (e.g. bacterial origins of replication) or undesirable (e.g. antibiotic resistance genes). Removing these elements may improve the safety profile of DNA for the delivery of vaccines. Here we describe a novel, double-stranded, linear DNA construct produced by an enzymatic process that solely encodes an antigen expression cassette, comprising antigen, promoter, polyA tail and telomeric ends. We compared these constructs (called ‘Doggybones’ because of their shape) with conventional plasmid DNA. Using luciferase-expressing constructs, we demonstrated that expression levels were equivalent between Doggybones and plasmids both in vitro and in vivo. When mice were immunized with DNA constructs expressing the HIV envelope protein gp140, equivalent humoral and cellular responses were induced. Immunizations with either construct type expressing haemagluttinin were protective against H1N1 influenza challenge. This is the first example of an effective DNA vaccine which can be produced on a large scale by enzymatic processes.
机译:使用DNA递送疫苗抗原具有许多优势,包括易于制造和成本降低。但是,大多数DNA疫苗是质粒,必须在细菌培养物中生长,从而需要对于有效的基因递送(例如细菌的复制起点)或不必要的(例如抗生素抗性基因)而言不必要的元件。去除这些元素可以改善DNA运送疫苗的安全性。在这里,我们描述了一种通过酶促过程产生的新颖的双链线性DNA构建体,该过程仅编码抗原表达盒,包括抗原,启动子,polyA尾巴和端粒末端。我们将这些构建体(由于其形状而称为“ Doggybones”)与常规质粒DNA进行了比较。使用表达荧光素酶的构建体,我们证明了在体外和体内,Doggybones和质粒之间的表达水平是相等的。当用表达HIV包膜蛋白gp140的DNA构建体免疫小鼠时,诱导了同等的体液和细胞反应。用表达血凝素的任何一种构建体类型进行的免疫均可预防H1N1流感病毒攻击。这是可以通过酶促方法大规模生产的有效DNA疫苗的第一个例子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号